| Online-Ressource |
Verfasst von: | Kruse, Sebastian [VerfasserIn]  |
| Büchler-Schäff, Marleen [VerfasserIn]  |
| Uhl, Philipp [VerfasserIn]  |
| Sauter, Max [VerfasserIn]  |
| Yang, Ruwen [VerfasserIn]  |
| Mier, Walter [VerfasserIn]  |
Titel: | Therapeutic vaccination using minimal HPV16 epitopes in a novel MHC-humanized murine HPV tumor model |
Verf.angabe: | Sebastian Kruse, Marleen Büchler, Philipp Uhl, Max Sauter, Philipp Scherer, Tammy C.T. Lan, Samantha Zottnick, Alexandra Klevenz, Ruwen Yang, Frank Rösl, Walter Mier & Angelika B. Riemer |
Jahr: | 2019 |
Jahr des Originals: | 2018 |
Teil: | volume:8 |
| year:2019 |
| number:1 |
Fussnoten: | Published online: 29 October 2018 ; Gesehen am /05.06.2019 |
Titel Quelle: | Enthalten in: OncoImmunology |
Ort Quelle: | Abingdon : Taylor & Franics, 2012 |
Jahr Quelle: | 2019 |
Band/Heft Quelle: | 8(2019,1) Artikel-Nummer e1524694, ? Seiten |
ISSN Quelle: | 2162-402X |
Abstract: | Therapeutic vaccination as a treatment option for HPV-induced cancers is actively pursued because the two HPV proteins E6 and E7 represent ideal targets for immunotherapy, as they are non-self and expressed in all tumor stages. MHC-humanized mice are valuable tools for the study of therapeutic cancer vaccines - given the availability of a suitable tumor model. Here, we present for the first time an HPV16 tumor model suitable for fully MHC-humanized A2.DR1 mice, PAP-A2 cells, which in contrast to existing HPV16 tumor models allows the exclusive study of HLA-A2- and DR1-mediated immune responses, without any interfering murine MHC-presented epitopes. We used several HPV16 epitopes that were shown to be presented on human cervical cancer cells by mass spectrometry for therapeutic anti-tumor vaccination in the new tumor model. All epitopes were immunogenic when rendered amphiphilic by incorporation into a molecule containing stearic acids. Prophylactic and therapeutic vaccination experiments with the epitope E7/11-19 demonstrated that effective immune responses could be induced with these vaccination approaches in A2.DR1 mice. Interestingly, the combination of E7/11-19 with other immunogenic HPV16 E6/E7 epitopes caused a reduction of vaccine efficacy, although all tested combinations resulted in a survival benefit. In summary, we present the first HPV16 tumor model for exclusive studies of HLA-A2-mediated anti-HPV tumor immune responses and show anti-tumor efficacy of minimal epitope vaccines. |
DOI: | doi:10.1080/2162402X.2018.1524694 |
URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext: https://doi.org/10.1080/2162402X.2018.1524694 |
| DOI: https://doi.org/10.1080/2162402X.2018.1524694 |
Datenträger: | Online-Ressource |
Sprache: | eng |
Sach-SW: | A2.DR1 |
| Cancer immunotherapy |
| HLA-humanized mouse model |
| human papillomavirus (HPV) |
| PAP-A2 |
| therapeutic vaccination |
K10plus-PPN: | 1666836508 |
Verknüpfungen: | → Zeitschrift |
Therapeutic vaccination using minimal HPV16 epitopes in a novel MHC-humanized murine HPV tumor model / Kruse, Sebastian [VerfasserIn]; 2019 (Online-Ressource)